136 Weingartl et al., “Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets,” J VIROL (Nov. 2004), doi: 10.1128/JVI.78.22.12672-12676.2004
137 Kam et al., “Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro,” VACCINE (August 22, 2006) doi: 10.1016/j.vaccine.2006.08.011
138 Agrawal et al., “Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus,” HUM VACCIN IMMUNOTHER (June 7, 2016), doi: 10.1080/21645515.2016.1177688
139 Hashem et al. “A highly immunogenic, protective, and safe adenovirus-based vaccine expressing middle east respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model”. J INFECT DIS. (July 4, 2019) doi: 10.1093/infdis/jiz137
140 Children’s Health Defense, “The Dengue Vaccine: A Cautionary Tale” (Aug. 25, 2020), childrenshealthdefense.org/news/the-dengue-vaccine-a-cautionary-tale/
141 Rachel L. Roper and Kristina E Rehm, “SARS vaccines: where are we?,” Expert Review of Vaccines, vol. 8, no. 7 (2009): 887–898, doi:10.1586/erv.09.43 (Jan. 9, 2014), ncbi.nlm.nih.gov/pmc/articles/PMC7105754/
142 Conor Skelding, “Fauci email dump includes ‘sick’ March Madness-style virus bracket,” New York Post, (Jun 5, 2021). https://nypost.com/2021/06/05/fauci-files-include-sick-march-madness-style-virus-bracket/
ChildrensHealthDefense.org/fauci-book
childrenshd.org/fauci-book
For updates, new citations and references, and new information about topics in this chapter:
CHAPTER 12
GERM GAMES
War Games: Genesis of the Biosecurity State
“Those who would give up essential liberty, to purchase a little temporary safety, deserve neither liberty nor safety.”
—Benjamin Franklin
“Many of us are pondering when things will return to normal. The short response is: never. Nothing will ever return to the “broken” sense of normalcy that prevailed prior to the crisis because the coronavirus pandemic marks a fundamental inflection point in our global trajectory.”
—Klaus Schwab, The Great Reset (July 2020)
“I want to be straight with you: There will be no return to the old normal for the foreseeable future.”
—Tedros Adhanom Ghebreyesus, World Health Organization Director-General
History of Bioweapons
The United States began its first large-scale offensive bioweapons research during World War II in the spring of 1943 on orders from President Franklin Roosevelt, as a collaboration between the US military and its pharmaceutical industry partners. Pharma titan George W. Merck ran the Pentagon’s offensive bioweapons program while simultaneously directing his drug manufacturing behemoth. Merck boasted that his team could deliver biowarfare agents without vast expenditures or constructing huge facilities. Another advantage of bioweapons, he remarked, was that their development could proceed under the guise of legitimate medical research.
The intelligence agencies were involved in the top secret program from the outset. George Merck’s hands-on employee, Frank Olson, was an American bacteriologist, biological warfare scientist, and CIA officer.1 He worked for the United States Army Biological Warfare Laboratories (USBWL) at Fort Detrick with Merck and the US military developing the US bioweapons and psywarfare arsenal. Project Artichoke was an experimental CIA interrogation program that used psychoactive drugs like LSD in pursuit of “enhanced” interrogation methods. The project was part of a larger CIA program exploring approaches for controlling both individuals and populations. Olson was involved with Project Artichoke with moral misgivings, beginning in May 1952: after watching a documentary on Protestant reformation leader Martin Luther, a conscience-stricken Olson informed his bosses he intended to quit the biowarfare program.2
Around the time of that announcement, Olson’s CIA colleague, Sidney Gottlieb, head of the CIA’s MKUltra program, covertly dosed him with LSD. A week later, on November 28, 1953, Olson plunged to his death from a window of New York’s Hotel Statler. The US government first described his death as a suicide, and then as misadventure. In 1975, the government admitted its guilt in the murder and offered Olson’s family an out-of-court settlement of $1,250,000, later reduced to $750,000, which they accepted with an official apology from President Gerald Ford and then-CIA Director William Colby.3
By 1969, the US bioweapons program had developed weapons of a “nuclear equivalence,” according to David Franz, who, for twenty-three years, served as commander of the US Army Medical Research Institute of Infectious Diseases (USAMRIID).4 The principal limitation, Franz acknowledged, was the difficulty of managing bioweapons so as to prevent accidental escape. Ironically, Franz would later play a key role in the Pentagon/Fauci gain-of-function programs leading up to the COVID-19 pandemic.
It all ended—seemingly—in late 1969, when President Nixon traveled to Fort Detrick to announce the closure of America’s bioweapons program for moral and strategic reasons. America signed the Biological Weapons Convention in 1972—forbidding development, use, and stockpiling of biological weapons—and mothballed most of its labs.5 But the agreement—a supplement to the Geneva Convention—left thousands of scientists, military contractors, and Pentagon caliphs as stranded assets yearning for the program’s revival.
The treaty also included a yawning loophole: it allowed production of anthrax and other biological warfare agents for vaccine production. The Pentagon and CIA spooks continued to cultivate bioweapon seed stock. Between 1983 and 1988, Searle Pharmaceuticals CEO Donald Rumsfeld, acting as Ronald Reagan’s envoy in Iraq, arranged for the top-secret shipment of tons of chemical and biological armaments, including anthrax and bubonic plague, to Iraqi President Saddam Hussein, hoping to reverse his looming defeat by Iran’s million-man army. Ayatollah Khomeini’s victorious Iranian forces were then routing Saddam in their war over the Persian Gulf. The Bush administration feared the impact on global oil supplies if Iran prevailed in that conflict.6